重组凝血因子市场规模、份额及成长分析（依产品类型、血友病类型、最终用户及地区）－2025-2032 年产业预测

重组凝血因子市场规模在 2023 年价值 140 亿美元，预计将从 2024 年的 149.7 亿美元增长到 2032 年的 255.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.9%。

由于血友病和其他出血性疾病的盛行率不断上升，以及消费者对血浆解决方案的需求不断增加，重组凝血因子市场正在经历成长。这些因子包括因子 VIII、因子 IX 和血管性血友病因子，是透过重组 DNA 技术产生的，提供了更安全的替代方案，具有更低的感染疾病传播风险。由于研发力度活性化以及核准产品的增加，市场正在进一步扩大。然而，挑战依然存在，例如与更便宜的血浆替代品相比，血友病治疗的成本很高。儘管有这些障碍，但由于各地区越来越多地采用血友病预防治疗方法，全球市场前景依然乐观。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

重组凝血因子市场规模（依产品类型及复合年增长率）（2025-2032）

• 市场概览
• 重组Ⅷ因子
• 重组IX因子
• 血管性血友病因子

重组凝血因子市场规模（依血友病类型划分）及复合年增长率（2025-2032）

• 市场概览
• A型血友病A
• B型血友病

重组凝血因子市场规模（依最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 诊所
• 研究组织

重组凝血因子市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Novo Nordisk（Denmark）
• Takeda Pharmaceutical Company Limited（Japan）
• Bayer AG（Germany）
• Pfizer Inc.（USA）
• Swedish Orphan Biovitrum AB（Sobi）（Sweden）
• CSL Behring（Australia）
• Roche Holding AG（Switzerland）
• Sanofi（France）
• Grifols, SA（Spain）
• Biogen Inc.（USA）
• Kedrion SpA（Italy）
• Octapharma AG（Switzerland）
• Bio Products Laboratory Ltd.（UK）
• LFB SA（France）
• GC Pharma（South Korea）
• CSL Limited（Australia）
• Freeline Therapeutics（UK）
• Sangamo Therapeutics, Inc.（USA）

结论和建议

Recombinant Coagulation Factors Market size was valued at USD 14.0 billion in 2023 and is poised to grow from USD 14.97 billion in 2024 to USD 25.52 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The recombinant coagulation factors market is witnessing growth driven by the rising incidence of hemophilia and other bleeding disorders, alongside increasing consumer demand for plasma-derived solutions. These factors, including Factor VIII, Factor IX, and von Willebrand factor, are produced through recombinant DNA technology, offering safer alternatives with a lower risk of infectious agent transmission. The boost in research and development efforts, coupled with a growing number of product approvals, further enhances market expansion. However, challenges persist, including the high costs associated with hemophilia treatment compared to cheaper plasma alternatives. Despite these obstacles, the global market outlook remains positive, fueled by the expanding adoption of prophylactic treatments for hemophilia across various regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Coagulation Factors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Coagulation Factors Market Segments Analysis

Global Recombinant Coagulation Factors Market is segmented by Product Type, Hemophilia Type, End User and region. Based on Product Type, the market is segmented into Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor. Based on Hemophilia Type, the market is segmented into Hemophilia A and Hemophilia B. Based on End User, the market is segmented into Hospitals, Clinics and Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Recombinant Coagulation Factors Market

The Recombinant Coagulation Factors market has experienced a steady rise in research and development spending and funding within the pharmaceutical and biotechnology sectors. Leading market participants are dedicating substantial resources to the development of innovative, technologically advanced products, which enhances the adoption of Recombinant Coagulation Factors on a global scale, particularly in both developed and developing nations. This surge in utilization is a significant driver of growth for the global market. Moreover, the growing number of product approvals for new recombinant coagulation factors serves as a critical factor facilitating market expansion, further underlining the sector's dynamic progress and innovation.

Restraints in the Recombinant Coagulation Factors Market

The recombinant coagulation factors market faces significant restraints due to the high costs associated with hemophilia treatments when compared to lower-cost plasma coagulation options available in the market. Additionally, the presence of alternative treatment options further impacts the growth potential of the global recombinant coagulation factors market. These alternatives not only provide more affordable solutions for patients but also contribute to a competitive landscape that can hinder the adoption and demand for recombinant factors. As a result, these financial considerations and market alternatives present substantial challenges to the expansion of the recombinant coagulation factors market.

Market Trends of the Recombinant Coagulation Factors Market

The global recombinant coagulation factors market is witnessing significant growth, primarily fueled by the increasing prevalence of blood disorders, particularly haemophilia, and the corresponding rising adoption of advanced treatment options. Patients and healthcare providers are favoring recombinant coagulation factors due to their safety profile, lower risk of transmission of infectious agents, and improved efficacy over traditional plasma-derived factors. Additionally, ongoing advancements in biotechnological processes and the introduction of innovative therapies are further propelling market expansion. As awareness regarding these therapies rises and healthcare systems emphasize personalized medicine, the demand for recombinant coagulation factors is expected to surge, defining a robust market trend.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant Coagulation Factors Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Recombinant Factor VIII
• Recombinant Factor IX
• Von Willebrand Factor

Global Recombinant Coagulation Factors Market Size by Hemophilia Type & CAGR (2025-2032)

• Market Overview
• Hemophilia A
• Hemophilia B

Global Recombinant Coagulation Factors Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Research Organizations

Global Recombinant Coagulation Factors Market Size & CAGR (2025-2032)

• North America (Product Type, Hemophilia Type, End User)
  • US
  • Canada
• Europe (Product Type, Hemophilia Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Hemophilia Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Hemophilia Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Hemophilia Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Swedish Orphan Biovitrum AB (Sobi) (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Pharma (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Freeline Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations